Search

Displaying results 1021 - 1030 of 3917 in total
  1. Drug

    Lindane

    go.drugbank.com/drugs/DB00431
    ApprovedWithdrawn

    In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical … Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment.

  2. Drug

    Rilzabrutinib

    go.drugbank.com/drugs/DB17709
    ApprovedInvestigational

    Rilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune

  3. Drug

    Acebutolol

    go.drugbank.com/drugs/DB01193
    ApprovedInvestigational

    A cardioselective beta-adrenergic antagonist with little effect on the bronchial receptors. … The drug has stabilizing and quinidine-like effects on cardiac rhythm as well as weak inherent sympathomimetic action.

  4. Drug

    Terpin hydrate

    go.drugbank.com/drugs/DB13163
    ApprovedWithdrawn

    It was popular in the United States since the late nineteenth century, but was removed from marketed medications in the 1990s after FDA stated that "based on evidence currently available, there are inadequate

  5. Drug

    Fursultiamine

    go.drugbank.com/drugs/DB08966
    Approved

    It has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.

  6. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    [L47865] On August 14, 2023, the drug was also approved for the treatment of cervical dystonia. … [A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines.

  7. Drug

    Vorapaxar

    go.drugbank.com/drugs/DB09030
    Approved

    By inhibiting PAR-1, a thrombin receptor expressed on platelets, vorapaxar prevents thrombin-related platelet aggregation.

  8. Drug

    Mirdametinib

    go.drugbank.com/drugs/DB07101
    ApprovedInvestigational

    On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1).

  9. Drug

    Kebuzone

    go.drugbank.com/drugs/DB08940
    Investigational

    Kebuzone (also known as ketophenylbutazone ) is a non-steroidal anti-inflammatory drug.

    Categories: Analgesics, Non-Narcotic, Non COX-2 selective NSAIDS
  10. Drug

    Alprazolam

    go.drugbank.com/drugs/DB00404
    ApprovedIllicitInvestigational

    [A18125] Alprazolam was given FDA approval on October 16, 1981.[L6148]